A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of raf/MEK/extracellular signal-regulated kinase

Molecular and Cellular Biology

Volumn 33, Issue 20, 2013, Pages 4051-4067

  Wu, Pui Kei ^a   Hong, Seung Keun ^a   Veeranki, Sudhakar ^a   Karkhanis, Mansi ^a   Starenki, Dmytro ^a   Plaza, Jose A ^a   Park, Jong In ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; HEAT SHOCK PROTEIN 70; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN MORTALIN; RAF PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LUCIFERASES; MAP KINASE KINASE 1; MAP KINASE KINASE 2; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886885205     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00021-13     Document Type: Article

References (58)

1. Shaul YD, Seger R. 2007. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim. Biophys. Acta 1773:1213-1226.
2. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. 2007. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773:1263-1284.
3. Roberts PJ, Der CJ. 2007. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310.
4. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602.
5. Zhu J, Woods D, McMahon M, Bishop JM. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12:2997-3007.
6. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. 1998. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12:3008-3019.
7. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. 2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-724.
8. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M. 2005. Tumour biology: senescence in premalignant tumours. Nature 436: 642.
9. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dorken B, Jenuwein T, Schmitt CA. 2005. Oncogeneinduced senescence as an initial barrier in lymphoma development. Nature 436:660-665.
10. Mooi WJ, Peeper DS. 2006. Oncogene-induced cell senescence-halting on the road to cancer. N. Engl. J. Med. 355:1037-1046.
11. Courtois-Cox S, Jones SL, Cichowski K. 2008. Many roads lead to oncogene-induced senescence. Oncogene 27:2801-2809.
12. McDuffFK, Turner SD. 2011. Jailbreak: oncogene-induced senescence and its evasion. Cell. Signal. 23:6-13.
13. Daugaard M, Rohde M, Jaattela M. 2007. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett. 581:3702-3710.
14. Deocaris CC, Widodo N, Ishii T, Kaul SC, Wadhwa R. 2007. Functional significance of minor structural and expression changes in stress chaperone mortalin. Ann. N. Y. Acad. Sci. 1119:165-175.
15. Kaul SC, Deocaris CC, Wadhwa R. 2007. Three faces of mortalin: a housekeeper, guardian and killer. Exp. Gerontol. 42:263-274.
16. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR, Kaul SC. 2006. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int. J. Cancer 118:2973-2980.
17. Wadhwa R, Takano S, Taira K, Kaul SC. 2004. Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells. J. Gene Med. 6:439-444.
18. Wadhwa R, Takano S, Kaur K, Aida S, Yaguchi T, Kaul Z, Hirano T, Taira K, Kaul SC. 2005. Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. Biochem. J. 391: 185-190.
19. Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, Mitsui Y, Kaul SC. 1998. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J. Biol. Chem. 273:29586-29591.
20. Wadhwa R, Yaguchi T, Hasan MK, Taira K, Kaul SC. 2003. Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. Biochem. Biophys. Res. Commun. 302:735-742.
21. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R, Luk JM. 2011. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ. 18:1046-1056.
22. Hong SK, Yoon S, Moelling C, Arthan D, Park JI. 2009. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. J. Biol. Chem. 284:33006-33018.
23. Samuels ML, Weber MJ, Bishop JM, McMahon M. 1993. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human Raf-1 protein kinase. Mol. Cell. Biol. 13:6241-6252.
24. Vindelov LL, Christensen IJ, Nissen NI. 1983. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323-327.
25. Mostoslavsky G, Fabian AJ, Rooney S, Alt FW, Mulligan RC. 2006. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc. Natl. Acad. Sci. U. S. A. 103:16406-16411.
26. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L. 2003. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 33:401-406.
27. Beier F, Taylor AC, LuValle P. 1999. The Raf-1/MEK/ERK pathway regulates the expression of the p21Cip1/Waf1 gene in chondrocytes. J. Biol. Chem. 274:30273-30279.
28. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2___CT method. Methods 25: 402-408.
29. Hong SK, Kim JH, Lin MF, Park JI. 2011. The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Exp. Cell Res. 317:2671-2682.
30. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.
31. Abbas T, Dutta A. 2009. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9:400-414.
32. Javelaud D, Besançon F. 2002. Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio. J. Biol. Chem. 277:37949-37954.
33. Staversky RJ, Vitiello PF, Gehen SC, Helt CE, Rahman A, Keng PC, O'Reilly MA. 2006. p21Cip1/Waf1/Sdi1 protects against hyperoxia by maintaining expression of Bcl-XL. Free Radic. Biol. Med. 41:601-609.
34. Vitiello PF, Staversky RJ, Gehen SC, Johnston CJ, Finkelstein JN, Wright TW, O'Reilly MA. 2006. p21Cip1 protection against hyperoxia requires Bcl-XL and is uncoupled from its ability to suppress growth. Am. J. Pathol. 168:1838-1847.
35. Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL, Espinosa JM. 2012. The p53 circuit board. Biochim. Biophys. Acta 1825:229-244.
36. Shin SY, Kim CG, Lim Y, Lee YH. 2011. The ETS family transcription factor ELK-1 regulates induction of the cell cycle-regulatory gene p21Waf1/Cip1 and theBAXgene in sodium arsenite-exposedhumankeratinocyteHaCaTcells. J. Biol. Chem. 286:26860-26872.
37. Lazar DF, Wiese RJ, Brady MJ, Mastick CC, Waters SB, Yamauchi K, Pessin JE, Cuatrecasas P, Saltiel AR. 1995. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J. Biol. Chem. 270:20801-20807.
38. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. 2008. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 68:3429-3439.
39. O'Shaughnessy EC, Palani S, Collins JJ, Sarkar CA. 2011. Tunable signal processing in synthetic MAP kinase cascades. Cell 144:119-131.
40. Kampinga HH, Craig EA. 2010. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat. Rev. Mol. Cell Biol. 11: 579-592.
41. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, Jr, Tucker MA, Dracopoli NC. 1994. Germline p16 mutations in familial melanoma. Nat. Genet. 8:15-21.
42. Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H. 2012. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J. Invest. Dermatol. 132:356-364.
43. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, Dong MQ, Frangou CG, Yates JR, III, Wright PE, Han J. 2007. PRAK is essential for ras-induced senescence and tumor suppression. Cell 128:295-308.
44. Papetti M, Wontakal SN, Stopka T, Skoultchi AI. 2010. GATA-1 directly regulates p21 gene expression during erythroid differentiation. Cell Cycle 9:1972-1980.
45. Chew YC, Adhikary G, Wilson GM, Xu W, Eckert RL. 2012. Sulforaphane induction of p21Cip1 cyclin-dependent kinase inhibitor expression requires p53 and Sp1 transcription factors and is p53-dependent. J. Biol. Chem. 287:16168-16178.
46. Solit DB, Rosen N. 2011. Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 364:772-774.
47. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445:661-665.
48. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
49. Bonneau B, Prudent J, Popgeorgiev N, Gillet G. 2013. Non-apoptotic roles of Bcl-2 family: the calcium connection. Biochim. Biophys. Acta 1833:1755-1765.
50. Merrick BA, Walker VR, He C, Patterson RM, Selkirk JK. 1997. Induction of novel Grp75 isoforms by 2-deoxyglucose in human and murine fibroblasts. Cancer Lett. 119:185-190.
51. Ward PS, Thompson CB. 2012. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297-308.
52. Gabai VL, Sherman MY, Yaglom JA. 2010. HSP72 depletion suppresses H2AX activation by genotoxic stresses via p53/p21 signaling. Oncogene 29:1952-1962.
53. Hupp TR, Meek DW, Midgley CA, Lane DP. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875-886.
54. O'Callaghan-Sunol C, Gabai VL, Sherman MY. 2007. Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res. 67:11779-11788.
55. Walerych D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, King FW, Helwak A, Boros J, Zylicz A, Zylicz M. 2004. Hsp90 chaperones wild-type p53 tumor suppressor protein. J. Biol. Chem. 279:48836-48845.
56. Walerych D, Olszewski MB, Gutkowska M, Helwak A, Zylicz M, Zylicz A. 2009. Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions. Oncogene 28:4284-4294.
57. Bukau B, Horwich AL. 1998. The Hsp70 and Hsp60 chaperone machines. Cell 92:351-366.
58. Khalil AA, Kabapy NF, Deraz SF, Smith C. 2011. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim. Biophys. Acta 1816:89-104.